# AMP 2026 Committee and Subdivision Annual Reports

**Board of Directors**

| | |
|---|---|
| President | Aaron D. Bossler, M.D., Ph.D. |
| President-Elect; | |
| Awards and Strategic Opportunities Committee Chair | Yassmine M.N. Akkari, Ph.D. |
| Past President and Nominating Committee Chair | Jane S. Gibson, Ph.D. |
| Secretary-Treasurer and Finance Committee Chair | Jonathan Nowak, M.D., Ph.D. |
| Clinical Practice Committee Chair | Alanna Church, M.D. |
| Economic Affairs Committee Chair | Jay Patel, M.D. |
| International Affairs Committee | Rami Mahfouz, M.D., MPH |
| Membership Affairs Committee Chair | Jennifer Morrissette, Ph.D. |
| Professional Relations Committee Chair | Eric Konnick, M.D., M.S. |
| Program Committee Chair | Annette Kim, M.D., Ph.D. |
| Publication & Communication Committee Chair | Lynne Abruzzo, M.D., Ph.D. |
| Training & Education Committee Chair | Valentina Nardi, M.D. |
| Genetics Subdivision Chair | Kristy Crooks, Ph.D. |
| Hematopathology Subdivision Chair | Mark Ewalt, M.D. |
| Infectious Diseases Subdivision Chair | Joseph D.C. Yao, M.D. |
| Informatics Subdivision Chair | Julie Hirschhorn, Ph.D. |
| Solid Tumors Subdivision Chair | Jaclyn Hechtman, M.D. |
| Early Career Member | Emilia Calvaresi, M.D., Ph.D. |
| Early Career Member | Sara Akhavanfard, M.D., Ph.D. |
| Chief Executive Officer | Laurie S. Menser, CAE |

# AMP Awards Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Yassmine M.N. Akkari, Ph.D. |
| Member | Margaret Gulley, M.D. |
| Member | Shelby Melton, M.D. |
| Member | Shi Yang, M.D. |
| Member | Anna Yemelyanova, M.D. |
| Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The Awards Committee consists of 5 members (4 appointed) who oversee the nomination and selection of the recipient of the Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award, and, if determined applicable, the recipient(s) of the Meritorious Service Award(s). The Committee evaluates the current awards, addresses the need for new awards, and conducts the formal nomination process for potential award recipients.

The President-Elect serves as the Chair of the Awards Committee. The remaining 4 committee members are appointed by the Board for a two-year, renewable term, up to a maximum of six years. The selection of incoming committee member(s) is conducted by the committee and the candidates' names are brought forward for Board approval and appointment.

**Timeline for AMP Awards**

The Awards Committee coordinated the timing of the AMP recognition awards as follows:

- Ongoing: Nominations from the Board, Committees, and Membership
- April: Review and selection by Awards Committee
- April through May: Notification of recipients
- May through September: Assess need for new recognition awards, if any

**Selected Award Recipients**

- 2026 Jeffrey A. Kant Leadership Award: Laura J. Tafe, M.D.
- 2026 Meritorious Service Award: Daniel E. Sabath, M.D., Ph.D
- 2028 Award for Excellence in Molecular Diagnostics: To be announced in Spring 2028

# AMP Clinical Practice Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Alanna Church, M.D. |
| Genetics Subdivision Representative | Molly Schroeder, Ph.D. |
| Genetics Subdivision Representative | Panieh Terraf, Ph.D. |
| Hematopathology Subdivision Representative | Peng Wang, M.D., Ph.D. |
| Hematopathology Subdivision Representative | Kevin E. Fisher, M.D., Ph.D. |
| Infectious Diseases Subdivision Representative | Mark D. Gonzalez, Ph.D. |
| Infectious Diseases Subdivision Representative | Heather Glasgow, Ph.D. |
| Informatics Subdivision Representative | Thomas D. Lee, M.D., Ph.D. |
| Informatics Subdivision Representative | Jeffrey Gagan, M.D., Ph.D. |
| Solid Tumors Subdivision Representative | Deepika Sirohi, M.D. |
| Solid Tumors Subdivision Representative | Allison Cushman–Vokoun, M.D., Ph.D. |
| Junior Member | David Twa, M.D., Ph.D. |
| Junior Member | Rebecca Ramesh, M.D. |
| Technologist Member | Timothy Daniels, B.S. |
| Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The Clinical Practice Committee (CPC) is comprised of AMP members with expertise in one or more of the molecular specialties: infectious diseases, hematopathology, solid tumors, genetics, and informatics. Its purpose is to address the challenges of clinical laboratories and, therefore, improve the service we provide. The AMP Clinical Practice Guidelines Program is comprised of multiple AMP-led working groups that plan, organize, and coordinate efforts such as practice guidelines, sample exchanges, reporting surveys, validation and quality control measures, and advocate for policies that will advance the practice of high-quality clinical molecular pathology services. The majority of these projects include representation from other professional organizations and groups. AMP's External Representatives & Organizational Engagements Program additionally fosters collaboration by providing AMP subject matter experts to clinical practice projects led by other professional organizations and groups.

**2026 ACTIVITIES:**

**Accomplishments**

- Multiple manuscripts submitted, and multiple AMP working group projects are underway.
- Two new projects launched; additional projects are launching soon.
- Assisted AMP Advocacy committees and the various Subdivisions with input for their various initiatives where applicable.
- Multiple AMP Associate Members are working on CPC working groups as Junior Members.

**Requests from the CPC**

- We encourage all AMP members to alert the Board or appropriate committees when laboratory guidelines or recommendations are opened for public comment.
- We encourage AMP members to actively contribute to calls for information from the CPC.
- Suggestions from AMP members for new CPC initiatives are always welcome! Visit https://www.amp.org/clinical-practice/clinical-practice-overview/ for more details or email ampclinicalpractice@amp.org.

**AMP Clinical Practice Working Groups / Task Forces**

| Working Group / Task Force | Members |
|---|---|
| AI Task Force | Julie Hirschhorn (Chair), Ratilal Akabari, Yassmine Akkari, Jamal Benhamida, Aaron Bossler, Rachel Burnside, Emilia Calvaresi, Alexis Carter, Timothy Daniels, Jeffrey Gagan, Hassan Ghani, Andrew Hughes, Eric Konnick, Thomas Lee, Timothy O'Leary, Jay Patel, Nirali Patel, Ryan Schmidt, Meghan Starolis, and Richard Wong |
| NGS Utility for Assessment of T/B-cell Clonality | David Viswanatha (Chair), Maria Arcila, Devon Chabot-Richards (SH representative), Christopher Coldren, Timothy Greiner, Joseph Khoury (CAP representative), Habibe Kurt, Keyur Patel, and David Wu |
| Molecular MRD Monitoring in Acute Myeloid Leukemia | Keyur Patel (Chair), Dale Bixby, Noah Brown, Hong Fang, Rashmi Goswami, Marian Harris, Annette Kim, Nikhil Patkar, Harrison Tsai, David Wu (SH representative), and Rena Xian (CAP representative) |
| CAP/IASLC/AMP Molecular Testing Guideline for Selection of Lung Cancer Patients for *EGFR* and *ALK* Tyrosine Kinase Inhibitors – Revision | Neal Lindeman (AMP Co-Chair), Maria Arcila, Dhananjay Chitale, David Kwiatkowski, Lynette Sholl, and Laura Tafe |
| CAP/AMP Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline | Antonia Sepulveda (AMP Co-Chair), Stacey Cohen, Allison Cushman-Vokoun, Wei Jiang, Ian King, and Benjamin Swanson |
| Validation of Next-Generation Sequencing Panels for Gene Fusion and Splice Variant Detection | Laura Tafe (Chair), Alanna Church (Co-Chair), Eduardo Castro-Echeverry, Marjorie David, Suneel Kamath (ASCO representative), Michael Kluk, Ravindra Kolhe (CAP representative), Christian Kunder, Andres Madrigal, Fatimah Nahhas, Valentina Nardi, and Igor Odintsov |
| Update of "Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists" | Marilyn Li (Chair), Cindy Vnencak-Jones (Co-Chair), Amir Behdad, Ozge Ceyhan-Birsoy (ACMG representative), Catherine Cottrell, Eric Duncavage, Melissa Gildenberg, Obi Griffith (CGC representative), Annette Kim (SH representative), Shashikant Kulkarni (ClinGen Cancer Variant Interpretation representative), Christine Lovly (ASCO representative), Jason Rosenbaum, Somak Roy, Eytan Stein (ASH representative), Lea Surrey (CAP representative), Scott Turner, and Kai Wang |
| Patient-friendly Biomarker Reporting | Rajyasree Emmadi (Chair), Allison Cushman-Vokoun, Jane Gibson, Julie Hirschhorn, Jennifer Morrissette, Irene Newsham, Sinchita Roy Chowdhuri, and Eric Vail |
| Standardization of Clinically Relevant Pharmacogenetic Alleles (PGx) Overview | Karen Weck (Chair), Victoria Pratt (Co-Chair), Makenzie Fulmer, Andrea Gaedigk (PharmVar representative), Houda Hachad, Yuan Ji (ACMG representative), Lisa Kalman, Reynold Ly, Ann Moyer (CAP representative), Stuart Scott, Amy Turner, Ron van Schaik (DPWG and ESPT representative), and Michelle Whirl-Carrillo (CPIC and PharmGKB representative) |
| ICC-WHO Classifications Hematopathology Subdivision Leadership Task Force | Eric Duncavage (Chair), Rena Xian (Co-Chair), Amir Behdad, Noah Brown, Jennifer Bynum, Joanna Conant, Mark Ewalt, Pawel Mroz, and Valentina Nardi |
| Clinical Validation of cfDNA and ctDNA Assays | Panieh Terraf (Chair), Christina Lockwood (Co-Chair), Navid Sadri, Rena Xian, Henning Stehr, Shamini Selvarajah, Pawel Mroz, Thuy Phung, Venkata Yellapantula, Mark Ewalt (CAP |

| | |
|---|---|
| | representative), Simon Patton (EMQN representative), Christian Rolfo (ISLB representative), Umang Swami (ASCO representative), and Samuel Harvey |
| Best Practice Guidance for AI and ML for Molecular Diagnostics Part 1 | Jeffrey Gagan (Chair), Andrea Sboner (Co-Chair), Jamal Benhamida, Emilia Calvaresi, Samuel Harvey, Thomas Lee, Annette Leon, Gwendolyn McMillin (ADLM representative), Pawel Mroz (CAP representative), and Weiwei Zhang |

**AMP External Representatives & Organizational Engagements Program**

| AMP Representative | Lead Organization(s); Other Collaborating Organization(s) | Workgroup / Committee |
|---|---|---|
| Robyn Temple-Smolkin | AcademyHealth; multiple other organizations | Scaling Cancer Biomarker Testing Initiative Workstream Launch Meeting; AMP is a Member Organization |
| Larissa Furtado | American Association for Cancer Research (AACR); SPROUT (Somatic Profiling for Pediatric Cancer, Refining our Understanding and Treatment) Working Group of Dana Farber Cancer Institute and Boston Children's Cancer Center | AACR / SPROUT Pediatric Molecular Guidelines Working Group |
| Ravindra Kolhe | American College of Medical Genetics and Genomics (ACMG) | Points to Consider for the Clinical Validation and Implementation of Optical Genome Mapping |
| Jianling Ji<br>Matija Snuderl | ACMG | Points to Consider for the Implementation of DNA Methylation Arrays for Clinical Diagnostics |
| Carolyn Sue Richards | ACMG | Incidental Findings in Inherited Diseases Update Workgroup |
| Scott Turner | ACMG; American Society of Human Genetics (ASHG), Cancer Genomics Consortium (CGC), EMQN, HUGO Gene Nomenclature Committee | Technical Laboratory Standards for Interpretation and Reporting of Acquired Copy-number Abnormalities and Copy-neutral Loss of Heterozygosity in Neoplastic Disorder |
| Alanna Church | ACMG; College of American Pathologists (CAP), CGC, International Society for the Study of Vascular Anomalies (ISSVA) | Vascular Anomalies and Somatic Overgrowth Disorders |
| Julie Gastier-Foster<br>Scott Topper | ACMG; ClinGen, CAP | Interpretation of Sequence Variants Update Workgroup |
| Shashirekha Shetty | ACMG; ClinGen, CAP | 2020 ACMG/ClinGen Technical Standards for Interpretation and Reporting of Constitutional Copy Number Variants (CNVs) Workgroup |
| Somak Roy<br>Fei Dong | ACMG; ClinGen, CAP, HUGO Gene Nomenclature Committee with representation from EMQN | Technical Standards for the Reporting and Sharing of Interpreted Genomic Variation in Journals Workgroup |

| | | |
|---|---|---|
| | and Association for Clinical Genomic Science | |
| Marco Leung<br>Zehra Ordulu | ACMG | Use of Sex and Gender Identifiers in Clinical and Laboratory Genetics and Genomics Workgroup |
| Marjorie David | American College of Surgeons American Joint Committee on Cancer (ACS AJCC) | Education Committee; AMP is a Member Organization |
| Eric Duncavage | Association of Community Cancer Centers (ACCC) | Advisory Committee |
| Dara Aisner<br>Sinchita Roy-Chowdhuri | ACCC | Operational Pathways in Lung Cancer |
| Michelle Shiller | ACCC | Cancer Diagnostics Advisory Committee |
| Rena Xian | American Society of Clinical Oncology (ASCO) | Cell-free DNA Testing Guideline Expert Panel |
| Dara Aisner<br>Laura Tafe | ASCO | Multi-Site Guideline Advisory Group |
| Kristy Crooks | American Society of Pharmacovigilance | Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community |
| Robyn Temple-Smolkin | BLOODPAC | Clinician Education & Access Working Group |
| Aatur Singhi | BLOODPAC | Early Cancer Detection and Screening Working Group |
| Timothy O'Leary | BLOODPAC | MRD/Multi-Cancer Early Detection Recommended Data Elements Working |
| Michael Dorschner | BLOODPAC | MRD Clinical Validation Working Group |
| Jacquelyn Reuther | BLOODPAC | bTMB Analytical Validation Working Group |
| Rina Kansal | BLOODPAC | CHIP Working Group |
| Bing Melody Zhang | BLOODPAC | Molecular Residual Disease (MRD) Analytical Validation Working Group |
| Richard Hickman | BLOODPAC | CSF Brain Tumor Working Group |
| Christina Lockwood | BLOODPAC | Advisory Committee, Analytical Validation Working Group, and Minimal Data Elements Working Group |
| J. Bryan | BLOODPAC | MRD Clinical Utility (MRD CU) Working Group |
| Emilia Calvaresi | BLOODPAC | Multi-Omics AI Working Group |
| Sanja Dacic | Cancer Support Community (CSC) | Lung Biomarker Digital Tool Advisory Board |
| Mehdi Nassiri | Centers for Disease Control and Prevention (CDC) | Forum on Adoption of Standards for Laboratory Data Exchange and Interoperability |
| Robyn Temple-Smolkin | CDC | Surge Capacity MOU Partners; AMP is a Member Organization |

| | | |
|---|---|---|
| Marilyn Li | ClinGen | Somatic Cancer Clinical Domain Workgroup |
| Somak Roy | Clinical Laboratory Standards Institute (CLSI) | Document Development Committee on Sequencing Bioinformatics for Human Genetics and Oncology (MM25) work group |
| Christina Lockwood | CLSI | Document Development Committee on Liquid Biopsy Methods for Oncology (MM28) work group |
| Daniel Sabath | College of American Pathologists (CAP) | Molecular Oncology Committee |
| Ryan Schmidt | CAP | Clinical Grade HGVS Workgroup |
| Mark Ewalt | CAP; International Clinical Cytometry Society | Evaluation of Minimal Residual Disease in Acute Lymphoblastic Leukemia Guideline workgroup |
| Mehdi Nassiri | Food and Drug Administration (FDA) Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD) | SHIELD Consortium |
| Robyn Temple-Smolkin | FDA SHIELD | SHIELD Steering Committee;<br>AMP is a Member Organization |
| Maria Bettinotti | Foundation for the National Institutes of Health (FNIH) | Biomarkers Consortium Steering Committee for Inflammation and Immunity |
| Snehal Patel | FNIH | Biomarkers Consortium Steering Committee for Cancer |
| Jing Xu | FNIH | Steering Committee for Cancer: Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) work group |
| Robyn Temple-Smolkin | From Testing To Targeted Treatments (FT3) | FT3 Steering Committee;<br>AMP is a Member Organization |
| Henning Stehr | HL7 International | HL7 and HL7 Clinical Genomics Workgroup |
| Mary Beth Beasley | LUNGevity | Initiate Reflex Testing in NSCLC Workgroup |
| Robyn Temple-Smolkin | LUNGevity | Society Collaboration Action Workgroup |
| Robyn Temple-Smolkin | National Human Genome Research Institute (NHGRI) | Genomics-Enabled Learning Health System Network (gLHS) Steering Committee |
| Maria Arcila | Personalized Medicine Coalition | Steering Committee for Precision Oncology Roadmap |
| Yaolin Zhou<br>Joshua Deignan | Test Renaming for Understanding and Utilization (TRUU-Lab) coalition | Steering Committee |
| Kristy Crooks | U.S. Pharmacopeia (USP) | USP's Pharmacogenomics Laboratory Testing Roundtable |
| Valentina Nardi | Variant Interpretation for Cancer Consortium (VICC) | Gene Fusion Oncogenicity Work Group |
| Panieh Terraf | Variant Interpretation for Cancer Consortium (VICC) | Gene Fusion Curation Working Group |

| | | |
|---|---|---|
| Emilia Calvaresi | National Institute of Standards and Technology (NIST) | Genome in a Bottle Steering Committee |
| Antonia Sepulveda | World Health Organization International Agency for Research on Cancer (WHO IARC) | International Collaboration for Cancer Classification and Research (IC3R) |
| Panieh Terraf | WHO IC3R and IQNPath (International Quality Network for Pathology) | Expert Knowledge Judgement on Reporting Recommendations for ctDNA Testing in Cancer Management Meeting |

# AMP Economic Affairs Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Jay L. Patel, M.D., M.B.A. |
| Vice Chair, Coverage- Genetics and Oncology | Eric Vail, M.D. |
| Vice Chair, New Codes & Pricing (Genetics Subdivision Rep.) | Victoria Pratt, Ph.D. |
| Member (Informatics Subdivision Rep.) | Nicholas Bevins, Ph.D. |
| Member | Clarisa Blattner, B.S., C.P.C. |
| Junior Member | Molly Broache, DNP, RN, WHNP-BC |
| Member | Jay Brock, Ph.D. |
| Member | Shimul Chowdhury, Ph.D. |
| Member | Maude Champagne, M.B.A. |
| Member | Erin Graf, Ph.D. |
| Member | Lloyd Hutchinson, M.D. |
| Member | Rina Kansal, M.D. |
| Member | Medhi Nassiri, M.D. |
| Member | Ankita Patel, Ph.D. |
| Member | Keyur Patel, M.D., Ph.D. |
| Member | Salvatore Priore, M.D., Ph.D. |
| Member | Navid Sadri, M.D., Ph.D. |
| Member | Michelle Schoonmaker, Ph.D. |
| Member | Sarah Rapisardo, Ph.D. |
| Member (Hemepath Subdivision Rep.) | Patricia Tsang, M.D. |
| Member (Solid Tumor Subdivision Rep.) | Heather Williams, M.D. |
| Member (Infectious Disease Subdivision Rep.) | Joseph Yao, M.D. |
| Junior Member | Jessica Williams, M.D. |
| Member | Wei Zhang M.D., Ph.D. |
| Committee Advisor and Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D. |
| Committee Advisor | Samuel K. Caughron, M.D. |
| Committee Advisor | Pranil Chandra, D.O. |
| Committee Advisor | Jan A. Nowak, M.D., Ph.D. |
| Member (*Ex Officio* – Past President) | Jane S. Gibson, Ph.D. |
| Member (*Ex Officio* – PRC Chair) | Eric Konnick, M.D., M.S. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The Economic Affairs Committee (EAC) addresses, advises, and educates the AMP Board of Directors, membership, payors, legislators, and the public on economic issues of importance to the field of molecular pathology; prepares documents of importance to the Centers for Medicare & Medicaid Services (CMS); and develops and advocates for sound economic policies that promote the availability to patients of high-quality molecular pathology services. The Committee's scope encompasses short and long-term issues associated with the coding for molecular procedures, utilization of and coverage for molecular pathology, the determination of test pricing, and the potential economic impact of public policy decisions on molecular pathology practice. The Committee interacts with the American Medical Association (AMA), the College of American Pathologists (CAP), and other interested organizations in order to achieve common goals.

**2026 ACTIVITIES:**
The Centers for Medicare and Medicaid Services (CMS) have increasingly denied coverage and/or reduced payment for many medically necessary molecular pathology tests. These restrictions create a challenging environment for clinical practice and for innovators to translate new genomic discoveries into clinical applications. AMP employs government relations consultants, Jennifer Leib, Megan Anderson Brooks, Lindsey Trischler, and Mary Lee Watts of Innovation Policy Solutions, to advise the EAC on advocacy strategies and assist with fostering relationships between AMP, key federal agencies, and Congressional offices. Additionally, the EAC is supported by AMP Director, Public Policy and Advocacy, Gail Reese, and AMP Policy Manager, Samantha Pettersen. AMP continues to work with the broader professional community to address policy challenges and opportunities to engage and inform payors who aim to achieve rightful reimbursements for appropriate patient care services.

**Leadership:**
The Economic Affairs Committee is led by **Jay Patel, M.D.,** who serves as Chair of the committee.
**Victoria (Vicky) Pratt, Ph.D.,** Vice Chair, New Codes & Pricing Subcommittee
**Eric Vail, M.D.,** Vice Chair, Coverage, Genetics & Oncology

**Key Focus Issues:**
**The Protecting Access to Medicare Act (PAMA)**
The Protecting Access to Medicare Act of 2014 (PAMA) required laboratories that perform clinical diagnostic laboratory tests to report the amounts they are paid by private insurers for said tests to the Centers for Medicare and Medicaid Services (CMS). CMS then set the Medicare payment rates for laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS) based on the weighted median of the private payor data. Since 2014, AMP has continued to express significant concerns to CMS and Congress on various occasions about issues with the first PAMA exercise and how rates were established (e.g., data entity and reporting entities).

In early 2020, the Laboratory Access for Beneficiaries (LAB) Act was passed by Congress. The LAB Act was supported by AMP and addressed some of AMP's and other stakeholders' concerns with PAMA. It delayed the next round of data reporting until 2021 and delayed the timing for payment reductions under PAMA. Additionally, the LAB Act authorizes Medicare Payment Advisory Committee (MedPAC) to study the methodology CMS used to rate-set through PAMA.

Since the passage of the LAB Act, three additional pieces of legislation were passed: the Coronavirus Aid, Relief, and Economic Security Act (CARES Act; to address the COVID-19 public health crisis) included an additional one-year delay to PAMA and the Protecting Medicare and American Farmers from Sequester Cuts Act, which was passed in December 2021, also included an additional one-year delay to PAMA. The Consolidated Appropriations Act of 2023 was passed in December 2022. This revised the phase-in of payment reductions under the Medicare private payor rate-based CLFS. Statutory phase-in of payment reductions is extended through calendar year (CY) 2026. This created a 0.0 percent reduction for CY 2023 and determined that payment may not be reduced by more than 15 percent for CYs 2024 through 2026. On September 25th, 2024, a continuing resolution passed that included another one-year delay in PAMA cuts and reporting. In 2025, Continuing Appropriations and Extensions Act delayed reporting until January 30th, 2026. Following that, in 2026 the Consolidated Appropriations Act set PAMA reporting from May1st to Jul 31st, 2026 with a PAMA collection period from January 1st to June 30th, 2025.
The PAMA reporting data was released on September 21st, 2026. This data shows that there will be cuts to molecular tests. Showing the need for long term solutions to PAMA.

In Fall 2025, AMP met with House Committees of jurisdiction, Energy and Commerce and Ways and Means to discuss long-term PAMA solutions including the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

The RESULTS Act (S. 2761 / H.R. 5269) legislative option is heralded by ACLA. The RESULTS Act would reform PAMA by reducing the reporting by laboratories for widely available tests. While reducing the administrative and reporting burden on clinical laboratories on tests that do not meet the widely available test definition. Importantly, this legislation would also address steep payment cuts of up to 15% on approximately 820 widely used tests that are scheduled to begin January 1, 2027.

**Clinical Lab Fee Schedule for Calendar Year 2027**
During the summer, AMP provided written and oral comments to CMS on the Calendar Year (CY) 2027 CLFS. **Dr. Victoria Pratt** represented AMP at the annual CLFS meeting on June 10, 2026. She presented crosswalk recommendations for the new and reconsidered CY 2026 CLFS molecular pathology, genomic sequencing, optical genome mapping, and microbiology procedures.

Additionally, in July 2026, AMP also attended the Clinical Laboratory Diagnostic Tests (CDLTs) Public meeting at CMS headquarters, where the Advisory Panel (the Panel) on CDLTs reviewed and voted on crosswalk/gapfill pricing for new and reconsidered codes. PAMA established the Panel, which advises CMS on various issues under PAMA including payment rates for new tests, including whether to use the crosswalk or gapfill methodology for initial price determination. **Dr. Pranil Chandra** serves on the panel, nominated by AMP.

Following this year's PAMA reporting period, CMS convened the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests on September 15–16, 2026, to provide payment recommendations for codes with no reported PAMA data. Dr. Pratt presented AMP's recommendations for molecular pathology codes lacking reported data.

In late September, CMS released the CY 2027 CLFS Preliminary Determinations for the new and reconsidered services. While a majority of the preliminary CMS determinations align with AMP and other laboratory organizations' recommendations, a few of the preliminary recommendations provided by CMS vastly differ from both the Advisory Panel and AMP recommendations, along with stakeholder input and, in many cases, do not represent the best options for crosswalks. AMP is submitting comments reiterating our recommendations. Pricing determinations will be finalized later this year.

**Software as a Medical Service**
The proliferation of algorithmic services and artificial intelligence (AI) in laboratory processes has prompted various agencies and organizations to define these services and clarify the distinction between molecular pathology professional services and the software used within or in support of those services. This issue was addressed extensively in AMP's comments on the CMS Proposed Rule for CY 2027 Hospital Outpatient Prospective Payment System and the CMS CY 2027 Medicare Physician Fee Schedule.

In the OPPS proposed rule, CMS proposed moving certain services from the Clinical Laboratory Fee Schedule (CLFS) to New Technology Ambulatory Payment Classifications (APCs) on a temporary basis. AMP opposed this approach, emphasizing that software can be an integral component of laboratory procedures and that removing these services from the CLFS would create unnecessary administrative and financial burdens for laboratories. AMP also noted that the proposal was premature given the numerous related regulations and policy developments still underway.

AMP reiterated this position in its comments on the MPFS proposed rule, stating that it does not agree with or support CMS's assertion that software as a medical service (SaMS) is not an integral component of certain laboratory procedures. AMP has long maintained that laboratory analytics, including SaMS and other software tools used in conjunction with or as part of a laboratory procedure, can be essential to

clarifying results and enhancing the clinical utility of testing. AMP has also consistently advocated for these services to be appropriately regulated under CLIA.

**Medicare and Private Payer Coverage Policies**
Monitoring emerging policies continued to be a major focus of the Coverage subcommittee led by **Dr. Eric Vail.** AMP continues to advocate with CMS regarding coverage policy actions taken by Medicare Administrative Contractors (MACs). As of October 11, 2026, AMP has provided responses to various MACs for approximately 15 draft local coverage determinations (dLCDs). AMP and the College of American Pathologists (CAP) frequently collaborate and draft joint responses. The EAC is very thankful to the AMP members that have volunteered their time and subject matter expertise to assist in responding to the diverse coverage policy issues.

Additionally, earlier in 2026, AMP responded to one private payer coverage policy: Blue Cross Blue Shield Alabama's policy, Detection of Microorganism and Associated Syndromes and Elevance Health CG-LAB-39 - Respiratory Virus Testing for SARS-CoV-2, Influenza and RSV in the Outpatient Setting. Both policies need clarification on the correct scenarios for molecular testing and AMP proposed alternative language to ensure adequate patient access to testing.

**CPT Codes**
The EAC New Codes and Pricing Subcommittee, led by **Dr. Victoria Pratt**, advises and reviews new CPT code applications submitted to the Pathology Coding Caucus (PCC) and the Molecular Pathology Advisory Group (MPAG). **Dr. Samuel Caughron** continues to represent AMP as a voting member on the PCC. His voting is supported by the expertise and input from the New Codes Subcommittee. Throughout the year, the Subcommittee may submit new CPT code change proposals to AMA based on member need and input. The subcommittee also provided input to CMS' National Correct Coding Initiative (NCCI) to help ensure national correct coding methodologies of procedure to procedure (PTP) and medically unlikely edits (MUEs) for molecular procedures and is working with a broad group of stakeholders to address issues with updates to the NCCI manual.

**Outside Organization Involvement**
- **Dr. Jan Nowak** serves on the CPT Editorial Panel
- **Dr. Victoria Pratt,** Dr. Victoria serves as Co-Chair on the AMA Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG) and **Dr. Joseph Yao** serves as a member of the PLA-TAG.
- **Dr. Samuel Caughron** serves on the PCC, with **Dr. Keyur Patel** serving as the technical advisor.
- **Dr. Keyur Patel** serves as an AMP representative on the AMA Molecular Pathology Advisory Group (MPAG).

# AMP Finance Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Jonanthan Nowak, M.D., Ph.D. |
| President | Aaron D. Bossler, M.D., Ph.D. |
| President-Elect | Yassmine M.N. Akkari, Ph.D. |
| Past President | Jane S. Gibson, Ph.D. |
| Member | Lynne V. Abruzzo, M.D., Ph.D. |
| Member | Shelby Melton, M.D. |
| Member | Federico A. Monzon, M.D. |
| Chief Executive Officer (*Ex Officio*) | Laurie S. Menser, CAE |

The Finance Committee oversees AMP's financial affairs, including reviewing revenue & expense reports and recommending to the Board for approval an annual operating budget and the investment policy for the Association's assets.

# AMP International Affairs Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair and Membership Affairs Liaison (Middle East) | Rami Mahfouz, M.D. |
| Member (Southeast Asia) | Kenneth Chang, MBCHB |
| Member and Brazilian Affiliate Coordinator | Renata A. Coudry, M.D., Ph.D. |
| Member and Italy Affiliate Coordinator | Francesco Curcio, M.D. |
| Member and Korea Affiliate Liaison (East Asia) | Jieun Kim, M.D., Ph.D. |
| Member (Europe) | Fernando Lopez-Rios, M.D. |
| Member and India Affiliate Liaison (South Asia) | Deepak Mishra, M.D. |
| Member and Latin American Affiliate Liaison | Federico Monzon, M.D. |
| Member (South Asia) | Nikhil Patkar, M.D. |
| Member and German Affiliate Coordinator | Nicole Pfarr |
| Member and Australasian Affiliate Liaison | Laveniya Satgunaseelan, MBBS |
| Member and Brazilian Affiliate Coordinator | Roberta Sitnik, Ph.D. |
| Advisor | Helen Fernandes, Ph.D. |
| Advisor | Jin-Yeong Han, M.D., Ph.D. |
| Member (*Ex Officio* – President) | Aaron Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The International Affairs Committee (IAC):

- Enhances AMP as an international organization
- Promotes AMP's vision and mission internationally
- Facilitates international presence and participation in AMP groups and programs including AMP Europe and AMP Global
- Expands excellence in education and advocacy on behalf of patients, clinicians, and lab professionals to an international audience
- Enables the interaction of scientists and molecular pathologists in the various parts of the world
- Enhances AMP's international membership.

**2026 ACTIVITIES:**

- Approved and welcomed AMP's 12$^{th}$ International Affiliate member society: Association of Molecular Pathology Pakistan (AMPP), AMP's 13$^{th}$ International Affiliate member society: Ukrainian Association for Molecular Pathology & Genetics (UAMPG) and AMP's 14$^{th}$ International Affiliate member society: Swiss Society of Molecular Pathology (SSMP)
- Welcomed new AMPS, AMPP, and UAMPG Coordinators onto the committee
- Designed and released survey to collect data on the topic of Molecular Pathology in the Era of AI – results will be presented in a Q1 2027 webinar
- Selected Young Investigator Travel Awardees from Germany and Türkiye and IMPACT Awardees from India and Nepal to attend AMP Europe 2026 in Tallinn, Estonia.
- Selected International Trainee Travel Awardees from Nepal, China, and Pakistan and an IMPACT Awardee from Pakistan to attend the 2026 AMP Annual Meeting.
- Provided speaker support for the 13$^{th}$ Congress of the Molecular Pathology Association of India
- Awarded three International Membership Grants for individuals located in Brazil, Nepal, & Pakistan

# AMP Membership Affairs Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Jennifer Morrissette, Ph.D. |
| Vice-Chair | Marco Leung, Ph.D. |
| Member | Barbara Anderson, M.S. |
| Member | Tejus Bale, M.D., Ph.D. |
| Member, Representative to Training & Education | Yang Cao, Ph.D. |
| Member | Shuhua Cheng, Ph.D. |
| Member | Timothy Daniels, B.S. |
| Member | Kevin E. Fisher, M.D., Ph.D. |
| Member | Eitan Halper-Stromberg, M.D. |
| Member | Shuko Harada, M.D. |
| Member | Lisa Lansdon, Ph.D. |
| Member | Mariana Macedo, M.D., Ph.D. |
| Member | Rami Mahfouz, M.D. |
| Member, International Affairs Liaison | Rizwan Naeem, M.B.B.S |
| Member | Zehra Ordulu Sahin, M.D. |
| Member | Bijal Parikh, M.D., Ph.D. |
| Member | Honey Reddi, Ph.D. |
| Member | Jacquelyn Reuther, Ph.D. |
| Member | Sherin Shaaban, M.D., Ph.D. |
| Member | Marie Smithgall, M.D. |
| Member | Vibhuti Srivastava, Ph.D. |
| Member | David Suster, M.D. |
| Member | Panieh Terraf, Ph.D. |
| Member | Jessica Thomas, M.D. |
| Member | Cigdem Ussakli, M.D. |
| Member | Ying Wang, Ph.D. |
| Member | Shi Yang, M.D. |
| Junior Member | Jyotsna Singh, Ph.D. |
| Junior Member | Negar (Nina) Taheri, M.D. |
| Member (*Ex Officio* – President) | Aaron Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The AMP Membership Affairs Committee (MAC) provides recommendations to the Board and assistance to other committees regarding matters of membership and professional development. The committee plays an important role in helping AMP respond to the needs of its members and in facilitating the development of leaders in the field of molecular pathology.

Ongoing Responsibilities:

- Assesses and makes recommendations that will enhance the professional development of AMP members and the benefits of AMP membership
- Provides regular and timely notification to members about opportunities for special projects within or outside of standing committees and subdivisions
- Facilitates leadership development for AMP through various initiatives such as the ad hoc and junior member volunteer process

- Receives requests from Chairs or Board for ad hoc members to work on projects and manages the volunteer application process
- Surveys member volunteers annually regarding their volunteer service experiences
- Surveys the membership periodically regarding how well their membership in AMP meets their needs and how well AMP is serving the needs of the profession
- Surveys non-members to help identify barriers to membership in AMP
- Conducts a member recruitment and retention program

2025-2026 Accomplishments

- Selected:
    - Three recipients for the AMP 2026 Technologist Travel Awards.
    - Three recipients of the AMP 2026 Trailblazer Travel Award.
- Planned and hosted:
    - 2026 AMP Annual Meeting First Timer's Lunch with a focus on networking (in addition to providing information about AMP and the AMP Annual Meeting)
    - Two Innovation Spotlights: **(1) Want to Get Involved with AMP?** MAC Committee members Lisa Lansdon and Panieh Terraf talk about their experiences as micro-volunteers as a gateway to larger committee participation **(2) Ph.D. Career Paths in the Clinical Space** presented by Sherin Shaaban and Barbara Anderson to provide resources to Ph.D. candidates and students who are looking for career paths outside of academia.
- Developed committee member-driven projects to increase recruitment, retention, and member satisfaction. These projects include:
    - Followed up with first-time lunch attendees from 2025 Annual Meeting **(Complete)**
    - Created a "Seattle at-a-Glance" cheat sheet for first time meeting attendees **(Complete)**
    - Designed and distributed AMP First Timer's Lunch pens **(Complete)**
    - Worked with the Program Committee to enhance technologist specific content at the Annual Meeting **(Complete)**
    - Fostering membership opportunities for trainees in low-income countries **(Ongoing)**
    - Creating a comprehensive suite of projects to inform and recruit trainees as part of the new free Associate Membership program **(Ongoing)**
    - Expanding AMP's micro-volunteer program so that everyone who wants to share their time and expertise with AMP has an opportunity to do so. **(Ongoing)**
    - Continuing the Member Spotlights project. **(Ongoing)**
    - Publishing a white paper on the AMP website to be used as a resource for Ph.D.'s exploring career paths in the clinical space **(Ongoing)**
    - Created a survey targeting variant scientists to explore their needs in terms of membership, educational offerings, and professional development needs that will be launched in 2027 **(Ongoing)**
    - Work closely with the International Affairs and Training & Education Committees to ensure that membership needs are met around the globe and through educational offerings. **(Ongoing)**

# AMP Nominating Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Jane S. Gibson, Ph.D. |
| Genetics Subdivision Representative | Rachel D. Burnside, Ph.D., MBA |
| Genetics Subdivision Representative | Jennifer Laffin, Ph.D. |
| Hematopathology Subdivision Representative | Pawel Mroz, M.D., Ph.D. |
| Hematopathology Subdivision Representative | Rina Kansal, M.D. |
| Infectious Diseases Subdivision Representative | Rachel Liesman, Ph.D. |
| Infectious Diseases Subdivision Representative | Meghan W. Starolis, Ph.D. |
| Informatics Subdivision Representative | Weiwei Zhang, Ph.D. |
| Informatics Subdivision Representative | Christopher D. Coldren, Ph.D. |
| Solid Tumors Subdivision Representative | Sinchita Roy-Chowdhuri, M.D., Ph.D |
| Solid Tumors Subdivision Representative | Hui Chen, M.D., Ph.D. |
| Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The AMP Nominating Committee is composed of the Past President (Chair) and two representatives from each subdivision. The chair and subdivision representatives are responsible for recruiting qualified AMP members to run for elected offices. A ballot is compiled and made available for voting by all current Regular AMP members. Voting for elected offices takes place during the month of May or June each year.

**2026 ACTIVITIES:**

The Nominating Committee nominated Officers and Committee Representatives for the 2026 annual elections.

# AMP Professional Relations Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Eric Q. Konnick, M.D. |
| Vice Chair | Karen Weck, M.D. |
| Member | Esther Babady, Ph.D. |
| Member (Infectious Disease Subdivision Rep.) | Heather Blakenship, Ph.D. |
| Member | Betsy Bove, Ph.D. |
| Member | J. Bryan, M.D. |
| Member (AMP Rep. to FASEB Science Policy Committee) | Emilia Calvaresi, M.D., Ph.D. |
| Member | Meghan Delaney, D.O. |
| Member (Solid Tumors Subdivision Rep.) | Jennifer Dien Bard, Ph.D. |
| Member (Genetics Subdivision Rep.) | Xiaoli Du, Ph.D. |
| Member | Thủy Phùng , M.D., Ph.D. |
| Member | Jason Rosenbaum, M.D. |
| Member (Hemepath Subdivision Rep.) | Dan Sabath, M.D., Ph.D. |
| Member (Informatics Subdivision Rep.) | Ryan Schmidt, M.D., Ph.D. |
| Member | Laura Tafe, M.D. |
| Member | Thao Truong, Ph.D. |
| Member | Oana Vele, M.D. |
| Member | Yaolin Zhou, M.D. |
| Junior Member | Elizabeth C. Connor, M.D. |
| Junior Member | Sam Harvey, M.D., Ph.D. |
| Junior Member | Pamela Robertson, Ph.D. |
| Junior Member | Rosalie Sterner, M.D., Ph.D. |
| Committee Advisor | Jordan Laser, M.D. |
| Committee Advisor | Jill Murrell, Ph.D. |
| Member (Ex officio – President) | Aaron Bossler, M.D. Ph.D. |
| Member (Ex officio – President-Elect) | Yassmine M.N. Akkari, Ph.D. |
| Member (Ex officio – Past President) | Jane S. Gibson, Ph.D. |
| Member (Ex officio – EAC Chair) | Jay Patel, M.D., M.B.A. |
| Member (Ex Officio – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The AMP Professional Relations Committee (PRC) is the primary liaison between AMP and other organizations for public policy issues other than reimbursement, which is the purview of the Economic Affairs Committee. Major responsibilities of the Committee include:

1. Communicating and coordinating activities with the appropriate government offices, coalitions, trade associations, and patient and professional organizations to inform policy discussions that have an impact on the practice of molecular pathology;
2. Developing AMP positions on emerging policy issues affecting molecular pathology;
3. Interacting with a wide variety of entities, including other professional associations, Congress and U.S. Federal Agencies such as CMS, FDA, CDC, DHHS;
4. Monitoring worldwide policy and regulatory changes that impact international embers and could impact the US regulatory environment; and
5. Advocating for policy changes in legislation and regulation that will advance the practice of molecular pathology.

The committee membership includes individuals employed in a variety of medical, scientific, institutional, academic and commercial capacities.

**2026 ACTIVITIES:**
The PRC continues to monitor the activities of, and in some cases work with, U.S Congress and federal agencies such as the U.S. Food and Drug administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) as well as federal advisory committees such as the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine. After extensive discussion, the committee drafts AMP's policy positions and comments to federal agencies and members of Congress. AMP's government relations consultants, Jennifer Leib, Megan Anderson Brooks, Mary Lee Watts, and Lindsey Trischler of Innovation Policy Solutions, LLC (IPS), inform the Committee of all policy and legislative activity, assist in drafting policy positions, provide advice regarding advocacy strategies, and guide AMP's presence on Capitol Hill. IPS along with AMP Director of Public Policy and Advocacy, Gail Reese and AMP Policy Manager, Samantha Pettersen, and when possible, Committee or other AMP members meet with congressional staff to educate them about issues relevant to molecular pathology, to offer AMP's expertise, and to advocate for AMP members' interests. (Note: As a 501c3 tax-exempt organization, AMP is prohibited from participating in any partisan activities and may not have a Political Action Committee (PAC). In addition, its direct and grassroots lobbying activities are limited per IRC 501h.)

**Leadership:**
The Professional Relation Committee is led by **Eric Konnick, M.D.,** who serves as Chair of the committee, and **Karen Weck, M.D.,** who serves as Vice Chair.

**CLIA Modernization Efforts**
AMP continues to pursue regulatory and legislative avenues to modernize CLIA. AMP PRC leadership and staff met with CMS CLIA program staff in January and June to discuss potential regulatory updates. CMS staff seemed open to modernizing CLIA during the meeting. Following this meeting, in July, CMS released "Request for Information (RFI); Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations." AMP's response emphasized maintaining strong quality standards while preserving the flexibility laboratory professionals need to develop, validate and modify testing procedures based on scientific evidence, clinical context, and patient needs. AMP also urged CMS to update CLIA to explicitly include molecular and genomic testing in its definition of "laboratory", and to reaffirm that AI and software used in laboratory medicine to generate clinical reports used in patient care fall clearly under the CLIA framework.

**CMS Fraud Initiatives**
The Trump Administration continues to make preventing fraud a key focus of its regulatory efforts. AMP as an organization shares the perspective that preventing and reducing fraud in Medicare is a high priority, however it is important to preserve patient access to legitimate genetic tests in any efforts to strengthen program integrity. AMP outlined the myriad of ways in which legitimate testing could be perceived as fraudulent or unnecessary in two key proposals from CMS in 2026:

- *Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) Request for Information (RFI)*
  AMP's response to the CRUSH RFI emphasized the critical role of genetic and genomic testing in improving patient outcomes through precision medicine while helping reduce overall healthcare costs. AMP urged CMS to strengthen fraud prevention efforts by improving oversight of billing patterns, reinforcing existing CPT and NCCI coding requirements, and working more closely with Medicare Administrative Contractors (MACs) to identify suspicious claims. AMP also encouraged CMS to maintain a robust multiple-MAC system rather than further consolidating authority. Importantly, AMP stressed that fraud prevention initiatives should be targeted and data-driven, without creating barriers that limit patient access to medically necessary molecular diagnostic testing.

- *Duplicative Lab Services and Interoperability*
  AMP urged CMS not to assume that duplicative laboratory testing is widespread, noting that repeat molecular and genetic tests are often medically necessary because they address different clinical

questions, use different specimens, or inform treatment decisions as a disease evolves. We recommended that CMS first establish a narrow, clinically appropriate definition of unnecessary duplicate testing and avoid relying solely on overlap in genes, variants, or analytes.

AMP also agreed with CMS that improving interoperability and data sharing across the healthcare system is important but cautioned that current standards are not yet mature enough to support broad new mandates. We highlighted limitations with existing data standards, challenges in exchanging complex genomic information, inconsistent implementation across laboratory and EHR systems, and continued reliance on unstructured reports. AMP urged CMS to prioritize development and testing of more robust interoperability standards, carefully assess implementation costs and operational burdens, and use caution when considering AI-based tools to identify duplicate testing, as they may not reliably distinguish clinically distinct molecular assays.

**Gene Patent Law**

In 2024 and 2025, AMP strongly advocated against The Patent Eligibility and Restoration Act, 2023 (S. 2140) which is an attempt to permit patents of genes, laws of nature and abstract ideas. This bill was introduced by Senator Coons (D-DE) and Tom Tillis (R-NC) and would revise Section 101 of the Patent Act, which defines patent eligibility. It would also vacate the Supreme Court decision, AMP v. Myriad. These efforts included:

- Submitting testimony to the Senate Committee on the Judiciary, Subcommittee on Intellectual Property Hearing on "the Patent Eligibility Restoration Act- Restoring Clarity, Certainty, and Predictability to the U.S Patent System;"
- Leading sign-on letters with over 90 stakeholders Opposing PERA; and
- Meeting with key congressional offices in both the House and Senate.

AMP continues to monitor developments related to PERA and remains actively engaged in efforts to prevent its passage in 2026, meeting with key stakeholders to advocate opposition to PERA. Additionally, on July 14th former AMP President, Debra Leonard, MD PhD, appeared as a witness in the U.S. Senate Judiciary Committee hearing "From Genes to Machines: The Patent Eligibility Debate," submitting testimony that outlined the devasting consequences its passage would have on patient access and scientific innovation. Additional questions for the record were submitted on August 28.

**Capitol Hill Happenings**

AMP continues to foster existing partnerships on Capitol Hill. AMP Advocacy participated in over 30 congressional meetings in 2026 that focused on gene patent law, laboratory diagnostics legislation and regulation, and the pushing for the passage of the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

**Patient Advocacy Group Engagement**

The Patient Engagement Workgroup continues to develop resources to help patients understand emerging molecular technologies and the work performed in molecular pathology laboratories. With input from subject matter experts across various specialties, the group has expanded its technical resources and educational offerings. In late 2025, the group developed a video explaining the difference between screening and diagnostic testing for Hepatitis C and is now finalizing a video on liquid biopsy testing.

**Collaborations**

AMP continues to participate in a wide-range of policy cooperations with laboratory groups and other professional societies, , such as the National Academies of Sciences, Engineering, and Medicine (NASEM) Roundtable on Genomics and Precision Health (AMP representative Dr. Vicky Pratt), Federation of American Societies for Experimental Biology (FASEB) (AMP representative Dr. Emilia Calvaresi), and the Personalized Medicine Coalition (PMC), Cancer Leadership Council, Coalition for Innovation Lab Testing, Laboratory Access and Benefits (LAB) Coalition.

# AMP Program Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Annette Kim, M.D., Ph.D. |
| Chair-Elect | Rena R. Xian, M.D. |
| Genetics Subdivision Representative | Sherin Shaaban, M.D., Ph.D. |
| Genetics Subdivision Representative | Ying Zou, M.D., Ph.D. |
| Hematopathlogy Subdivision Representative | Phillip D. Michaels, M.D. |
| Hematopathlogy Subdivision Representative | Rashmi Kanagal-Shamanna, M.D. |
| Infectious Diseases Subdivision Representative | Anisha Misra, Ph.D. |
| Infectious Diseases Subdivision Representative | Nicole J. Tarlton, Ph.D. |
| Informatics Subdivision Representative | Priya Velu, M.D., Ph.D. |
| Informatics Subdivision Representative | Andrea Sboner, Ph.D. |
| Solid Tumors Subdivision Representative | Fei Dong, M.D. |
| Solid Tumors Subdivision Representative | Tejus A. Bale, M.D., Ph.D. |
| Technical Topics Representative | Timothy Daniels, B.S. |
| Technical Topics Representative | Chandler Ho, M.S. |
| Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The Program Committee is responsible for the overall planning and organization of the AMP Annual Meeting, including development of the scientific program, review and selection of abstracts and platform presentations, and oversight of poster presentations. The Committee also judges the Technologist Poster Awards.

**2026 ACTIVITIES:**

The Program Committee developed the scientific program for the AMP 2026 Annual Meeting & Expo, scheduled for November 10–14, 2026, in Seattle, Washington. Committee members will also moderate scientific sessions, judge posters, and support onsite programming.

Recorded scientific content from the meeting is scheduled to be available in January 2027.

**2026 HIGHLIGHTS:**

The AMP 2026 Annual Meeting & Expo achieved a record-breaking number of abstract submissions, reflecting strong scientific engagement and continued interest in sharing the latest research and advancements in molecular diagnostics.

The scientific program also saw a 68% increase in member and attendee engagement opportunities through expanded Platform Presentation and Case Study sessions, along with additional Co-Moderator roles. These enhancements provided more opportunities for members to share their expertise, contribute to scientific discussions, and actively participate in the meeting.

Additionally, AMP 2026 marked the launch of Special Programs Day, expanding educational offerings through focused programming and collaborations with partner organizations. This new initiative provides additional opportunities for specialized learning and professional development beyond the core Annual Meeting scientific program.

# AMP Publications Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Lynne Abruzzo, M.D., Ph.D. |
| *JMD* Editor-in-Chief | Ronald M. Przygodzki, M.D. |
| Member | Yogesh Chander, Ph.D. |
| Junior Member | Mukul Divatia, M.D. |
| Member | Annacarolina Fabiana Lucia da Silva, M.D. |
| Member | Midhat S. Farooqi, M.D., Ph.D. |
| Member | Annette Leon, FACMG, Ph.D. |
| Member | Madhu M. Ouseph, M.D., Ph.D. |
| Member | Daniel Sabath, M.D., Ph.D. |
| Member | Zheng Jin Tu, Ph.D. |
| Member | Barbara A. Zehnbauer, Ph.D. |
| Member | Huanyu Wang, Ph.D. |
| *JMD* Managing Editor | Emily Essex |
| Member (*Ex Officio* – President) | Aaron Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:** Members of the Publications Committee are appointed by the Board to serve up to six (6) two-year, renewable terms, and a junior member to serve a two-year term.

- The Publications Committee has certain responsibilities for AMP's official journal, *The Journal of Molecular Diagnostics (JMD),* which is co-owned by the American Society for Investigative Pathology (ASIP), including advisory to AMP's Board and ASIP's Council regarding *JMD* policy issues; scope statement; business success; publisher Request for Proposal and selection; selection of Editors and Editorial Board members; performance expectations for Editors.
- The Publications Committee does not oversee *JMD's* production or editorial functions; however, it may request or receive information and make recommendations to the Editor-in-Chief and Managing Editor.
- The Committee reviews AMP member submissions of Case Reports for potential publication in *CAP Today*.
- The Committee holds a virtual meeting bi-monthly, meets face-to-face before the annual meeting, and communicates electronically throughout the year.

**2026 ACTIVITIES:**

- Reviewed and evaluated AMP Case Reports submissions for potential publication in *CAP Today*.
- Identified and recommended key *JMD* articles bi-monthly to feature in the *AMPlifications* newsletter.
- Created a list of potential topics and authors for *JMD* review articles, guest editorials, and spotlight features.
- Supported the Review Committee's recommendation to renew Ron's appointment for a second term as *JMD*'s Editor-in-Chief.
- Periodically reviewed and updated the AMP Wikipedia page to ensure accuracy and relevance.

**AMP Case Report authors published in *CAP Today* since November 2025**

| Title | Corresponding Author | Co-authors |
|---|---|---|
| *Identification of rare PML::RARA variant missed by traditional molecular testing* | Celeste Eno, Ph.D., D(ABMGG), Cedars-Sinai Medical Center, Los Angeles, California, US | • Parastou Tizro, M.D.<br>• Eric Vail, M.D.<br>• Ronald Paquette, M.D. |
| *NTRK1-Rearranged Spindle Cell Sarcoma in an Unusual Location: Molecular Confirmation Resolving a High-Grade Pediatric Sarcoma Differential* | Haiyan Qiu, Ph.D., D(ABMGG), Westchester Medical Center/New York Medical College, Valhalla, New York, US | • Kotaro Takeda, M.D. |
| *Ultra-hypermutated colorectal adenocarcinoma identified at relapse* | Eric Loo, M.D., Quest Diagnostics Nichols Institute, US | • Shayan Sheikholeslami, B.S. |
| *Hypermutated Stage IIC Colon Carcinoma with a Rare POLE Exonuclease Variant and Co-occurring MSH6 and PIK3CA Alterations* | Soma Chakraborty, M.D., Yale School of Medicine, New Haven, Connecticut, US | • Karin E. Finberg, M.D., Ph.D.<br>• Zenta Walther, M.D., Ph.D.<br>• Jill Lacy, M.D.<br>• Joanna Gibson, M.D., Ph.D. |
| *Therapy-Related Acute Myeloid Leukemia, in a Patient with BRCA1 Positive Breast Cancer and a DDX41 Possibly Germline Variant* | Ejas Palathingal Bava, M.D., Washington University, St. Louis, Missouri, US | • So Pooja Khonde, M.D.<br>• Reger Mikaeel, Ph.D.<br>• Alexa Dickson, Ph.D.<br>• Eric Duncavage, M.D., Ph.D.<br>• Kilannin Krysiak, Ph.D. |
| *Is Undifferentiated Sarcoma with EWSR1-POU5F1 Fusion a molecularly defined entity?* | Ejas Palathingal Bava, M.D., Washington University, St. Louis, Missouri, US | • Salvador Alejo, M.D., Ph.D.<br>• Farzeen Shabeer, MBBS<br>• Pooja Khonde, M.D.<br>• Janet M. Poulik, M.D. |
| *Comprehensive Molecular Characterization of an Aggressive Infant-Type Hemispheric Glioma with a Novel PRKAR2A::ALK Fusion* | Mine Yilmaz, M.D., Columbia University, New York, New York, US | • Sidra Zaheer, M.D.<br>• Craig Soderquist, M.D.<br>Mahesh Mansukhani, M.D.<br>• Susan Hsiao, M.D.<br>• Marie Smithgall, M.D. |
| *Discordance of FLT3-ITD mutation testing in Acute Myeloid Leukemia between specimens: a discussion of prognosis implications and reporting options* | Nea Fride, University of Wisconsin-Madison, Madison, Wisconsin, US | • Matthew Contreras, M.D.<br>• William M Rehrauer, Ph.D. |

**Requests from the Publications Committee**

- We encourage AMP members to serve as reviewers for the *Journal of Molecular Diagnostics.* Please register an account on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.
- We encourage AMP members to submit Case Reports for potential publication in *CAP Today*. More information about the program and online submission portal is available on our website.

# AMP Strategic Opportunities Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Yassmine M. N. Akkari, Ph.D. |
| Board Member | Alanna Church, M.D. |
| Board Member | Jonathan Nowak, M.D., Ph.D. |
| Member | Michael Hadjisavas |
| Member | Federico A. Monzon, M.D. |
| Member | Nirali M. Patel, M.D. |
| Member | Ester Stein, M.S. |
| President *(Ex Officio – President)* | Aaron D. Bossler, M.D., Ph.D. |
| Chief Executive Officer (*Ex Officio – Chief Executive Officer*) | Laurie Menser, CAE |

**PURPOSE SUMMARY:** The Strategic Opportunities Committee (SOC) assesses the opportunities and challenges in the molecular pathology profession and other environments that affect AMP interests, including:

- assessing trends and activities in the broad environment external to AMP, *i.e.,* "horizon scanning"
- identifying and assessing external threats that could prevent AMP from attaining its goals
- identifying and assessing external opportunities that can help AMP attain its goals
- identifying organizations for potential relationships that can help AMP attain its goals

It also advises, conducts research for, or provides information to the Board as requested.

# AMP Training and Education Committee Annual Report, 2026

**COMMITTEE MEMBERS:**

| | |
|---|---|
| Chair | Valentina Nardi, M.D. |
| Genetics Subdivision Representative | Madina Sukhanova, Ph.D. |
| Genetics Subdivision Representative | Vibhuti Srivastava, Ph.D. |
| Hematopathology Subdivision Representative | Richard Wong, M.D. Ph.D |
| Hematopathology Subdivision Representative | Susan E. Harley, M.D. |
| Infectious Diseases Subdivision Representative | Rebekah Dumm, Ph.D. |
| Infectious Diseases Subdivision Representative | Heba Mostafa, M.D., Ph.D. |
| Informatics Subdivision Representative | Robert Bell, M.D. |
| Informatics Subdivision Representative | Heather M. Blankenship, Ph.D. |
| Solid Tumors Subdivision Representative | Erica Vormittag-Nocito, M.D. |
| Solid Tumors Subdivision Representative | James P. Solomon, M.D., Ph.D. |
| Junior Member | Ashley Barlev, M.D., Ph.D. |
| Junior Member | Xinxiu Xu, Ph.D. |
| Medical Technologist Member | Barbara Anderson, Ph.D. |
| Medical Technologist Member | Krupa Jani, M.S. |
| Membership Affairs Committee Liaison | Yang Cao, Ph.D. |
| Member (*Ex Officio* – President) | Aaron D. Bossler, M.D., Ph.D. |
| Member (*Ex Officio* – Chief Executive Officer) | Laurie S. Menser, CAE |

**PURPOSE SUMMARY:**

The Training and Education (T&E) Committee is comprised of representatives from each of AMP's subdivisions: genetics, hematopathology, infectious diseases, informatics, and solid tumors as well as technologist representatives, junior members, and a liaison from the Membership Affairs Committees (MAC). It oversees important issues such as education and certification in molecular pathology and mentoring of trainees, as well as developing educational programs for different audiences.

**2026 ACTIVITIES:**

**AMP 2026 Annual Meeting & Expo Activities:**

***Early Bird Sessions at the Annual Meeting & Expo - Case Studies Presented by Trainees or Technologists:***

The T&E Committee hosted an opportunity for fellows, residents, postdocs, graduate students, or technologists to present an interesting and/or challenging case study for the AMP 2026 Annual Meeting and Expo. This year, in an effort to increase case study presentation opportunities, an additional 4 Early Bird Case Study sessions were added to the program. Also new this year was the introduction of Case Study Lightning Talks presented at an innovation spotlight stage. Trainee/Technologist presenters in 2026 are listed below:

| | | | |
|---|---|---|---|
| *Case Studies in Genetics* | Hidden in plain sight: Resolving molecular discrepancies in melanoma | Nicholas Popp, MD/PhD | Mass General Brigham |
| | Long-Read Sequencing Improves Diagnostic Efficiency and Workflow for NCF1 Testing in Chronic Granulomatous Disease | Bradley Johnson, Masters | Mayo Clinic |
| | Beyond Hyperdiploidy: Optical Genome Mapping Reveals a High-Risk MYC::IGL | Fadi Abboodi, MD/PhD | Case Western Reserve |

| | | | |
|---|---|---|---|
| | Rearrangement and a Complex Genotype in a Patient with Multiple Myeloma | | University School of Medicine; University Hospitals Health System |
| | Beyond Routine Testing: Resolving a Complex IKBKG Rearrangement by Long-Read Sequencing and Optical Genome Mapping | Atlas Mashayekhi Sardoo, PhD | Greenwood Genetic Center |
| | Resolving Complex Prenatal Genomic Findings: A 10q26 Deletion with Confined Placental Mosaicism | Mohamed Omer, MBBS | Columbia University |
| | Haplotype-Resolved Methylation Profiling Identifies Allele-Specific Constitutional Methylation at a Single Nucleotide Variant Within a Putative MSH2 Regulatory Region in Lynch Syndrome | Yagiz Anasiz, PhD | University of Washington |
| | Beyond PAX8 and RET: Unmasking an NCOA6::PPARG Fusion in a "Molecularly Benign" Thyroid Nodule | Burak Muratoglu, MD | Henry Ford Health/Henry Ford Hospital |
| | Genomic Re-classification of a Recurrent "Undifferentiated Pleomorphic Sarcoma" of the Left Abdominal Wall as Dedifferentiated Liposarcoma via Integrated DNA/RNA NGS: Diagnostic, Prognostic, and Therapeutic Implications | Trinica George, Masters | 1Cell.Ai |
| | Rare Jumping 17q Translocation in a Complex Case of AML | Wesley Stansberry, PhD | University of Colorado |
| | Long-read Sequencing Identifies Novel Complex PAX2 Structural Variations in Renal Coloboma Syndrome | Francesco Emiliani, MD/PhD | Johns Hopkins Hospital |
| | Cat Got Your Eyes? Revisiting a Family History of Cat-Eye Syndrome Uncovers Familial Emanuel Syndrome | Andrew Nielson, MD | Vanderbilt University Medical Center |
| | The mystery of a Diamond-Blackfan anemia diagnosis: mining for answers | Jose Gomez-Garcia, DO/PhD | University of Minnesota |
| *Case Studies in Hematopathology* | When FGFR1 Strikes Again: A Rare RBPMS::FGFR1-Driven Myeloid Neoplasm and successful treatment of relapsed disease with Pemigatinib | Nicholas Dcunha, MBBS | MD Anderson Cancer Center |
| | Long read sequencing detection of cytogenetically cryptic insertion of RARA into the PML locus confirming acute promyelocytic leukemia | Kenneth Chen, DO/PhD | University of Washington |
| | Novel t(5;12) Fusion Involving ETV6/IL3 Detected by Optical Genome Mapping in Patient with Myelodysplastic Neoplasm with Eosinophilia | Xiaolan Fang, PhD | Henry Ford Health System |
| | Rare RUNX1::MIR99AHG Rearranged Acute Myeloid Leukemia with Dual FLT3-ITDs | Andrea Coetzee, MBCHB | Icahn School of Medicine at Mount Sinai |

| | | | |
|---|---|---|---|
| | Characterized by Nanopore Long Read Sequencing | | |
| | Whole-genome sequencing characterization of an ETV3::NCOA2-rearranged indeterminate dendritic cell tumor with evolution to a clonally related myeloid neoplasm | Salvador Alejo, MD/PhD | Washington University in St. Louis |
| | Matched plasma-WBC liquid biopsy for NSCLC incidentally identified KMT2A-rearranged acute myeloid leukemia | Paul Wadsworth, MD/PhD | MD Anderson Cancer Center |
| | When Hyperdiploidy Masks Near-Haploidy: Integrated Cytogenetic and SNP Microarray Characterization of Pediatric B-Lymphoblastic Leukemia | Jianyan Wen, MD | Baylor Scott & White Health |
| | B-acute lymphoblastic leukemia with masked hypodiploidy detected by whole-genome sequencing | Shakiba Hassanzadeh, MD | Washington University |
| *Case Studies in Solid Tumors* | An Unusual MYB::QKI Fusion-Positive High-Grade Glioma of the Cerebellum in an Older Adult | Di Tian, MD/PhD | MD Anderson Cancer Center |
| | Identification of ZFTA::RELA gene fusion in recurrent glial neoplasm previously diagnosed as glioblastoma highlights the critical role of molecular diagnostics in central nervous system tumor classification | Joan Shang, MD/PhD | Massachusetts General Hospital |
| | Beyond Microsatellite Instability: Deciphering High Tumor Mutation Burden in Clear Cell Renal Cell Carcinoma | Charlie Herndon, DO | University of California, San Francisco |
| | Melanoma with a NUTty Twist | Nakul Shankar, MD | Memorial Sloan Kettering Cancer Center |
| | A 9-year old male with an atypical fibro-osseous lesion in the femur | Juan Luis Gomez Marti, MD | Memorial Sloan Kettering Cancer Center |
| | Who is in the driver's seat? A report of a high-grade sarcoma with novel reciprocal BCOR::NCOA2 and NCOA2::BCOR fusions. | Maria Nelson, MD/PhD | University of Washington |
| | When Contamination Isn't: An Unexpected Cause of Specimen Identity Mismatch | Marta Rodriguez Escriba, PhD | University of California San Francisco (UCSF) |
| | POLE-Mutated Uterine Carcinosarcoma with Subclonal p53 Abnormality: A Classification Challenge | Sarah Farran, MD | University of Iowa Health Care |
| | A Molecular Red Flag: An Unexpected KRAS Mutation Reveals Papillary Renal Neoplasm with Reverse Polarity | Guang Yang, MD/PhD | Mayo Clinic |
| | Ultramutated POLE-Mutant IDH-Wildtype High-Grade Glioma in a Patient with Early-Onset Colorectal Carcinoma: A Case Suggestive of Polymerase Proofreading-Associated Cancer Predisposition. | Amira Othman, MD | Queen's University |

| | | | |
|---|---|---|---|
| | Collision Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma and Poorly Differentiated Adenocarcinoma | Nikunj Shah, DO | University of Miami / Jackson Health System |
| | POLE p.S297F Mutation in Pulmonary Sarcomatoid Carcinoma: A Rare Molecular Alteration with Potential Therapeutic Implications | Priyanka Batra, MD | University of Chicago (Endeavor Health) |
| *Lightning Talk Case Studies in Infectious Diseases* | When Culture Fails: Diagnosis of Ureaplasma Septic Arthritis by Targeted Metagenomic Next Generation Sequencing | Saina Beitari, PhD | Children's Hospital Los Angeles |
| *Lightning Talk Case Studies in Informatics* | Multiplex Plasma Biomarker and APOE ε4 Integration Predicts Amyloid-PET Status Across the Alzheimer's Disease Clinical Continuum | Paul Hung, PhD | Tandia |
| *Lightning Talk Case Studies in Hematopathology* | Clonally Identical but Phenotypically Discrepant: Co-Occurring PTCL, NOS and T-ALL with Cryptic PDGFRA Rearrangements and Its Therapeutic Implication | Aida Richardson, MD/PhD | Northwestern University Feinberg School of Medicine/ Ann & Robert H. Lurie Children's Hospital of Chicago |
| | RAD5 Nonsense Mutation in AML with DEK::NUP214 fusion: Critical Implications for Next-Generation Sequencing Panel Design, and Germline Assessment and fusion detection | Divya Mamilla, MBBS | Mount Sinai Hospital |

***The Molecular Genetic Pathology Fellowship Program Directors (MGP PD) Council***

The MGP Program Directors (MGP PD) Council consists of Jadee Neff (Chair), Kevin Fisher (Chair-Elect), and Bijal Parikh (Past-Chair). Richard Wong acts as the T&E committee representative to this group. The MGP PD Council facilitates the discussions of the MGP Program Directors Working Group and responds to the ABP and ACGME on matters related to MGP Fellowship programs. This year, they successfully completed the second NRMP Fellowship Match Recruitment for 2027-2028. They also implemented a common application, FellowshipsCAS, to streamline the application process for fellows applying to MGP Fellowships. The MGP program directors met at the AMP 2026 Annual Meeting & Expo, to discuss the continuation of the match process and the utility of FellowshipsCAS.

***The Education Community of Practice (EdCoP) Group***

The AMP Education Community of Practice Group is led by Yang Cao with working group members Thomas Lee, Lulu Sun, Erica Vormittag-Nocito, and Xinxiu Xu. In 2026, the working group released their 2025 Annual Meeting session on Integrating Bioinformatics Education into Clinical and Laboratory Training as an online broadcast. Following the broadcast, the working group began conducting a Bioinformatics Education Survey to determine current practices and needs in teaching bioinformatics. The EdCoP group held a meeting at the AMP Annual Meeting and Expo highlighting strategies for teaching and communicating with pathology trainees from a range of backgrounds and with different learning preferences.

***Innovation Spotlight Stages***

The T&E Committee hosted three Innovation Stages. One on AI use in trainee education, another on leadership at AMP, and the final one focused on tips for completing validations that ensure CAP and technical assessment readiness.

***Trainee Networking Luncheon***

Trainees were invited to connect with fellow trainees and other members of AMP while enjoying casual conversation and fun informal trivia. The event closed with a book drawing.

***Technologist Networking Luncheon***

The luncheon was a social opportunity to share working and learning experiences with others in the field of laboratory technology.

**Other 2026 T&E Activities**:

***2026 Live Webinars and Recorded Online Content (ROCs):***

| ***Date*** | ***Speaker*** | ***Title*** | ***NOTES (Registrants/Attendees)*** |
|---|---|---|---|
| | | | |
| ***Major Initiative: Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications*** | | | |
| 3/16/2026 | Ghayas Issa<br>Moderator: Pawel Mroz | Monitoring of Patients Receiving Menin Inhibitors for Acute Leukemia | 294/145 |
| 6/4/2026 | Lukas Bubendorf<br>Moderator: Fei Dong | MTAP Deficiency and Deletion in Cancer | 532/259 |
| 9/3/2026 | Stephanie Siegmund<br>Moderator: Erica Vormittag-Nocito | FGFR as a Biomarker: Diagnostic, Prognostic, and Therapeutic Perspectives | 520/251 |
| 10/29/2026 | Yuxuan Wang<br>Moderator: Pawel Mroz | Minimal Residual Disease in Solid Tumors: Principles and Applications of Circulating Tumor DNA | *Not available as of the date of this report.* |

| ***Date*** | ***Speaker*** | ***Title*** | ***NOTES (Registrants/Attendees)*** |
|---|---|---|---|
| | | | |
| ***Major Initiative: Streamlining Precision Oncology Testing Protocols Series*** | | | |
| 7/14/2026 | Allison M. Cushman–Vokoun, M.D., Ph.D.<br>Moderator: Andrew C. Nelson, M.D., Ph.D. | Streamlining Precision Oncology Testing Protocols: Lung Cancer as the Exemplar | 342/158 |
| 8/6/2026 | Andrew C. Nelson, M.D., Ph.D.<br>Moderator: Antonia R. Sepulveda, M.D., Ph.D. | From Specimen to Result: Streamlining Breast Cancer Biomarker Workflows in a Hybrid Academic-Community Health System | 287 / 120 |
| 10/20/2026 | Antonia R. Sepulveda, M.D., Ph.D.<br>Moderator: Allison M. Cushman–Vokoun, M.D., Ph.D. | From Specimen to Result: Streamlining Biomarker Workflows for Colorectal and Other Gastrointestinal Cancers | *Not available as of the date of this report.* |

| ***Date*** | ***Speaker*** | ***Title*** | ***NOTES (Registrants/Attendees)*** |
|---|---|---|---|
| ***Webinar Series: Horizons*** | | | |

| | | | |
|---|---|---|---|
| 9/15/2026 | Alexis Carter<br>Moderator: Heather Blakenship | From Bases to Bytes: An Introduction to AI and Machine Learning for the Molecular Professional | 299/197 |
| 10/6/2026 | Niaz Banaei<br>Moderator: Heba Mostafa | Evolving Paradigms in Infectious Disease Diagnostics: Tissue-Based Testing to Non-Invasive Advanced Molecular Platforms | *Not available as of the date of this report.* |
| | | | |
| ***Webinar Series: Horizons; Clinical Practice Webinars*** | | | |
| 3/5/2026 | Susan Hsiao<br>Moderator: Susan Harley | Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer | 811/275 |
| 8/12/2026 | Somak Roy<br>Moderator: Jason Merker | Development of a Body of Knowledge for the Clinical Bioinformatician Perspectives | 297/132 |
| 8/26/2026 | Annette Leon<br>Moderator: Weiwei Zhang | Clinical Bioinformatician Body of Knowledge—Molecular Diagnostics Core | 267/113 |
| 9/23/2026 | Andrea Sboner<br>Moderator: Robert Bell | Clinical Bioinformatician Body of Knowledge—Bioinformatics and Software Core | 334/132 |
| 10/14/2026 | Ryan Schmidt<br>Moderator: Thomas Lee | Clinical Bioinformatician Body of Knowledge—Clinical Laboratory Regulation and Data Security Core | *Not available as of the date of this report.* |
| | | | |
| ***Webinar Series: Trainee and Early Career Series*** | | | |
| 1/22/2026 | Panelists: Yassmine Akkari, Fei Dong, John Iafrate, Brynn Levy<br>Moderator: Adam Fisch | Driving Successful Mentorship as an Active Mentee | 173/84 |
| 4/7/2026 | Panelists: Kevin Fisher, M. Cristina Magallanes Hoyos, Heather Mason-Suares, Xinming Zhuo<br>Moderator: Adam Fisch | Embarking on a Job Search | 127/67 |
| 6/9/2026 | Panelists: Ngoni Faya, Mariam Mathew, Alexander Neil, Richard Wong<br>Moderator: Kenneth Ofori | Insights on Interview Preparation, Job Talk, and Negotiation | 177/70 |
| 9/29/2026 | Panelists: Barbara Nelson, John O'Shea, Laura Sack, Alyssa Wetzel<br>Moderator: Sara Akhavanfard | Excelling on the LGG Board Exam: Strategies, Resources, and Insights from Recent Fellowship Graduates | 174/106 |
| | | | |
| ***Education Community of Practice (EdCoP)*** | | | |
| 4/14/2026 | Weiwei Zhang, PhD, Jason Walker, MIM, Chad Vanderbilt, MD | Integrating Bioinformatics Education into Clinical and Laboratory Training (2025 Annual Meeting Session) | 834/312 |

***Online Education - AMPED™:***

The T&E Committee and staff have designed and developed educational materials for populating *educate.amp.org*. The AMP learning management system (LMS), *AMPED*™, attracted over 5,000 active users in 2025 (January 1, 2025-December 31, 2025) where 65% of the users were non-AMP members and about 43% from outside of the US. We currently have 155 educational products on our AMPED™ catalog. This includes on-demand webinars, course bundles, certificate programs, microlearning modules, and more.

- **AMP Certificate Programs:** Certificate programs are self-paced on-demand content designed to provide a deep dive on specific areas of interest. There are currently three certificate programs on our AMPED™ catalog.

- **AMP Flashcards:** We currently have three flashcard sets available on AMPED™. Some flashcard sets can also be used as study aids for ASCP certification exams. 1) acute myeloid leukemia, 2) Technologist in Molecular Biology: Laboratory Operations, and 3) Technologist in Molecular Biology: Molecular Techniques

- **FISE Question Bank:** This popular program, built in collaboration with the MGP-PD Council, provides fellows with a Fellowship In-Service Examination (FISE) at the beginning and at the end of their fellowship year. In addition, it can be used as a study tool for anybody throughout the year. New FISE questions are written by MGP faculty and reviewed by the T&E, while old questions are reviewed every other year by the Assessment & Content Editing Group (under the purview of the T&E). The question bank currently consists of >600 questions. AMP staff provides non-attributed results to participating fellowship institutions at the beginning of the fellowship year (in October) and at the end of the year (in May/June). 30 out of 42 Molecular Genetic Pathology programs participated in submitting new questions for 2026.

- **Molecular-in-My-Pocket™ cards:** The T&E Committee is continuosly expanding the Molecular-in-My-Pocket™ reference card collection. Five new cards (Molecular Techniques, Applications for Molecular Diagnostics for Infectious Diseases, Adult Tumors of the Kidney, https://www.amp.org/AMP/assets/File/education/MIMP/HemePredisposition.pdfInherited Disorders of Lipoprotein Metabolism) were created in 2026. Cards are reviewed annually by the Assessment Content Editing Group (under the purview of the T&E Committee) for accuracy and for any required updates. There have been more than 10,000 user visits to the MIMP card homepage from 11/2024 - 10/2025.

- **Molecular Genetic Pathology Review Course:** In May 2025, the **Molecular Genetic Pathology Review Course** was held as a 5-day virtual-live course. With 16 molecular genetic pathology expert faculty speaking on topics including molecular technologies, test validations and statistics, molecular oncology, infectious diseases and more, the course was designed to assist attendees in preparing for the MGP subspecialty certification exam as well as other exams in molecular pathology. This course was recorded and posted as a self-paced on demand course.

**AMPower Mentorship Program**

The Mentorship Program provides a structured format where AMP members can network, connect, and develop their careers. The Mentees select their Mentors from a database and meet approximately quarterly over two years. In 2026, the pilot program launched with 15 Mentor-Mentee pairs matching. An in-person event will be held at the 2026 AMP Annual Meeting to allow current participants to connect as well as to allow interested AMP members to learn more about the program and potentially become involved.

**Educational Partnerships/Collaborations, Co-Sponsorships, Companion Meetings**:

***United States and Canadian Academy of Pathology (USCAP) March 2026 – San Antonia, TX***
***The AMP 2026 Companion Society Symposium,***
"Molecular Testing in Oncology: Beyond Sequence Variants", was co-moderated by Lu Wang, M.D., Ph.D. and Anna Yemelyanova, MD.
**Speakers were:**

- Kenneth D. Aldape, M.D.
- Adam Shlien, Ph.D.
- Yen-Chun Liu, MD, Ph.D.

***College of American Pathologists (CAP) October 2026– Las Vegas, NV***
"Association for Molecular Pathology (AMP) Companion Society Session: When Pathological Morphology Falls Short: Reflex Molecular Tools for Infectious Disease Diagnosis", presented by Rebecca Yee, Ph.D.

# AMP Subdivision Leadership Annual Report, 2026

**SUBDIVISION LEADERSHIP**

| | Genetics | Hematopathology | Infectious Diseases | Informatics | Solid Tumors |
|---|---|---|---|---|---|
| **Chair** | Kristy Crooks | Mark Ewalt | Joseph D.C. Yao | Julie W. Hirschhorn | Jaclyn F. Hechtman |
| **Clinical Practice Committee** | Molly Schroeder | Peng Wang | Mark D. Gonzalez | Thomas D. Lee | Deepika Sirohi |
| | Panieh Terraf | Kevin E. Fisher | Heather Glasgow | Jeffrey Gagan | Allison Cushman-Vokoun |
| **Economic Affairs Committee** | Victoria Pratt | Patricia Tsang | Joseph D.C. Yao | Nick Bevins | Heather Williams |
| **Nominating Committee** | Rachel D. Burnside | Pawel Mroz | Rachael Liesman | Weiwei Zhang | Sinchita Roy-Chowdhuri |
| | Jennifer Laffin | Rina Kansal | Meghan W. Starolis | Christopher D. Coldren | Hui Chen |
| **Professional Relations Committee** | Xiaoli Du | Daniel Sabath | Heather Blankenship | Ryan Schmidt | J. Bryan |
| **Program Committee** | Sherin Shaaban | Phillip Michaels | Anisha Misra | Priya Velu | Fei Dong |
| | Ying Zou | Rashmi Kanagal-Shamanna | Nicole J. Tarlton | Andrea Sboner | Tejus A. Bale |
| **Training & Education Committee** | Madina Sukhanova | Richard Wong | Rebekah Drumm | Robert C. Bell | Erica R. Vormittag-Nocito |
| | Vibhuti Srivastava | Susan E. Harley | Heba Mostafa | Heather M. Blankenship | James P. Solomon |
| **Junior Member** | Husnain Ali | Muhammad Hussain | Mohanad Albayyaa | Ratilal Akabari | Pankaj K. Ahluwalia |

**PURPOSE SUMMARY:**

The Subdivision Leadership (SL) consists of a Chair, representatives to the Clinical Practice, Economic Affairs, Nominating, Program, Professional Relations, Training & Education Committees, and *ad hoc* representatives to the Subdivision Leadership groups from the Professional Relations and Economic Affairs Committees. Subdivision Chairs are responsible for the successful operation and development of the subdivision that they lead.

Each Subdivision Leadership group meets quarterly and functions in an AMP advisory panel of discipline-specific subject matter experts convened to address issues of importance to their Subdivision. They carry out their subdivision leadership responsibilities by:

- Assessing the needs and priorities of the Subdivision membership and the broader discipline.
- Offering feedback on relevant initiatives to the Clinical Practice Committee, Training and Education Committee, and other appropriate groups.
- Contributing ideas and recommendations for content at the Annual Meeting and other AMP educational events.
- Supporting the identification and nomination of prospective AMP volunteers and future leaders.
- Serving as a resource for advocacy efforts and related initiatives.

**2026 ACTIVITIES:**

All Subdivision Leadership groups contributed to the biannual Subdivision Spotlight email digests, highlighting AMP initiatives and JMD articles aligned with their members' interests. Additionally, provided feedback on ASCP's Effective Test Utilization (ETU) initiative, including potential molecular tests that meet the initiative's criteria and opportunities for molecular pathology to be represented in future ETU recommendations. Identified updates to the current list of certifications in the member database, including additional U.S. and international certifications to support efforts to better understand and update member profiles. Engaged in advocacy efforts related to the RESULTS Act and Patent Eligibility Restoration Act (PERA) by participating in AMP advocacy take-action initiatives and sharing them with colleagues. Contributed to projects across various AMP Committees.

**Genetics** - Served as AMP's internal genetics advisory board, guiding initiatives in clinical practice, advocacy, and education. Explored emerging areas of genetics and genomics, including variant interpretation and classification, next-generation sequencing (NGS) and long-read sequencing, pharmacogenomics, multi-omics, genome editing and cell and gene therapies, forensic applications, and advances in genomic databases and data representation. Contributed to the T&E Committee's Horizons webinar series' speaker selection and recommendations. Engaged in follow-up discussions on key issues and emerging considerations from the USP Pharmacogenetics Round Table, contributing to continued dialogue and efforts to advance priorities in pharmacogenetics.

**Hematopathology** - Served as AMP's internal advisory board for hematopathology, supporting the development of initiatives in clinical practice, advocacy, and education. Examined advances in hematopathology, including molecular classification and risk stratification of hematologic malignancies, minimal residual disease (MRD) assessment, next-generation sequencing (NGS) and other genomic approaches, advances in plasma cell neoplasms, immunophenotyping, and emerging applications of cellular and gene therapies, including CAR-T. Provided confidential feedback on the following BLOODPAC working group projects with AMP's external representatives: the MRD DLBCL Working Group review of the MRD Lexicon, best practices for distinguishing clonal hematopoiesis from tumor-derived variants in liquid biopsy, and analytical validation of tumor-agnostic ctDNA assays for molecular residual disease. Contributed expert input and recommendations for potential volunteers on the confidential CHIP new project proposal.

**Infectious Diseases** - Served as AMP's internal advisory board for infectious diseases, contributing to the development of initiatives in clinical practice, advocacy, and education. Monitored developments in infectious disease diagnostics, including next-generation sequencing (NGS) and metagenomic sequencing (mNGS), artificial intelligence and machine learning, antimicrobial resistance, emerging and re-emerging infectious diseases and pathogen surveillance, the microbiome, and advances in molecular approaches to infectious disease detection and characterization. Supported the maintenance of AMP's testing resource webpages for infectious diseases, including SARS-CoV-2, Mpox, H5N1 avian influenza, Ebola disease, and measles. Provided feedback on Elevance Health's draft of CG-LAB-39, including the proposed medical-necessity criteria for outpatient influenza, SARS-CoV-2, and RSV testing.

**Informatics** - Served as AMP's internal advisory board for informatics, supporting the development of initiatives in clinical practice, advocacy, and education. Evaluated key issues in clinical informatics, including bioinformatics pipelines and data analysis for next-generation sequencing (NGS), informatics approaches for metagenomic and multi-omics data, artificial intelligence and machine learning, and interoperability and integration of genomic data with electronic health records (EHRs), including HL7 standards. Provided expert feedback on the AMA's confidential draft outlining proposed documentation requirements for applicants seeking an AI-based CPT code.

Contributed to AMP's organizational response to the HHS Request for Information (RFI) on accelerating the adoption and use of AI in clinical care, including current regulatory challenges, relevant regulations, and potential unintended consequences.

**Solid Tumors** - Served as AMP's internal advisory board for solid tumors, contributing to the development of initiatives in clinical practice, advocacy, and education. Discussed evolving approaches to the clinical management of solid tumors, including precision oncology and molecular profiling, circulating tumor cells, gene fusions, homologous recombination deficiency (HRD), liquid biopsies, tumor mutational burden (TMB), and emerging biomarkers. Offered confidential feedback on the following BLOODPAC working group projects with AMP's external representatives: the MRD DLBCL Working Group review of the MRD Lexicon, best practices for distinguishing clonal hematopoiesis from tumor-derived variants in liquid biopsy, and analytical validation of tumor-agnostic ctDNA assays for molecular residual disease. Shared expert input and recommendations for potential volunteers on the confidential CHIP new project proposal.

**Requests from the Subdivision Leadership**

- We encourage all AMP members to alert their Subdivision Chair or Representatives to current or emerging specific needs that AMP should consider and address.
- We encourage AMP members to actively contribute to requests for information from their respective Subdivision Leadership.
- We encourage AMP members to serve as reviewers for the *Journal of Molecular Diagnostics.* Please register an account on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.